Lower Dose Preoperative Radiotherapy in Myxoid Liposarcoma
A phase 2 clinical trial, DOREMY, suggests that reducing the preoperative radiotherapy dose for myxoid liposarcoma can maintain oncologic safety while decreasing long-term side effects. The study involved 90 patients across Europe and the U.S. and showed promising results for dose de-escalation.
Why it matters
This research could lead to improved quality of life for cancer patients by reducing the toxicity associated with standard high-dose radiation treatments.
Lower Dose Preoperative Radiotherapy in Myxoid Liposarcoma - OncoDaily
The text is a straightforward summary of medical research findings with no political or subjective framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in